Novel vaccine prime and selective BCG boost: A new tuberculosis vaccine strategy for infants of HIV-infected mothers |
| |
| Authors: | Mark Hatherill Hassan Mahomed Willem Hanekom |
| |
| Affiliation: | 1. South African Tuberculosis Vaccine Initiative (SATVI), University of Cape Town, South Africa;2. Institute of Infectious Disease & Molecular Medicine, University of Cape Town, South Africa;3. School of Child & Adolescent Health, University of Cape Town, South Africa |
| |
| Abstract: | Novel tuberculosis vaccination strategies hinge on BCG priming, yet newborn BCG vaccination may cause BCG disease in HIV-infected infants. Viral-vectored or subunit prime vaccine, followed by delayed BCG boost only for HIV-uninfected infants, may be a safe alternative for all newborns, regardless of maternal HIV infection. This approach should be tested using new tuberculosis vaccine candidates. If safety and immunogenicity of a novel vaccine prime is established in infants of HIV-infected mothers, for whom newborn BCG carries unacceptable risk, this strategy might then be compared to conventional BCG prime and viral-vectored or subunit boost, and BCG alone, in HIV-unexposed infants. |
| |
| Keywords: | Tuberculosis BCG HIV Prime Boost |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
